Jyong BiotechMENS -0.90%10 EBIT per Share is $-0.03 as of Dec. 2025. GuruFocus rates MENS with a GF Score™ of 10/100. The stock has 3 warning signs investors should review. Among 1,174 Biotechnology companies, Jyong Biotech ranks worse than 68.99% on this metric.
Jyong Biotech's EBIT per Share for the
six
months ended in Dec. 2025 was $-0.02.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.03.
During the past 3 years, the average EBIT per Share Growth Rate was 0.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Jyong Biotech's EBIT per Share or its related term are showing as below:
MENS'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 0.9 Med: 3.2 Max: 5.5
Current: 0.9
During the past 5 years, the highest 3-Year average EBIT per Share Growth Rate of Jyong Biotech was 5.50% per year. The lowest was 0.90% per year. And the median was 3.20% per year.
MENS's 3-Year EBIT Growth Rate is ranked worse than 68.99% of 1174
companies
in the Biotechnology industry
Industry Median: 15.4
vs MENS: 0.90
Jyong Biotech's EBIT for the
six
months ended in Dec. 2025 was $-1.30 Mil.
Jyong Biotech (NAS:MENS) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Jyong Biotech EBIT per Share Related Terms
Jyong Biotech EBIT per Share Historical Data
* Premium members only.
The historical data trend for Jyong Biotech's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.03
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jyong Biotech (MENS) has a EBIT per Share of $-0.03 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Jyong Biotech and its competitors. According to the industry distribution chart, Jyong Biotech ranks #810 out of 1174 companies in the Biotechnology industry, placing it in the top 69%.
Is Jyong Biotech's EBIT per Share too high?
Jyong Biotech's current EBIT per Share is $-0.03. Based on the distribution chart, Jyong Biotech ranks #810 out of 1174 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Jyong Biotech has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Jyong Biotech's EBIT per Share compare to ENLV and CNTB?
According to the Biotechnology industry distribution chart, Jyong Biotech ranks #810 out of 1174 companies for EBIT per Share. This places Jyong Biotech in the lower half of its industry. The industry median EBIT per Share is 15.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.40, based on 1,174 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Jyong Biotech and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jyong Biotech's current EBIT per Share is $-0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jyong Biotech stock overvalued right now?
Jyong Biotech (MENS) has a current EBIT per Share of $-0.03. The current EBIT per Share is $-0.03. Jyong Biotech's overall GF Score™ is 10/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Jyong Biotech (MENS), the current EBIT per Share is $-0.03 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Jyong Biotech Ltd is research and develop new drugs for today's great unmet medical needs and planned to manufacture and sell new drugs after receiving regulatory approval. It is a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia. The Group operates and manages its business as a single segment in the research and development of novel therapeutics targeting unmet needs. The company's product pipeline includes MCS-2, PCP, IC.
10GF Score
Get the complete analysis for MENS
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MENS has been successfully added to your 